Covid-19: relationship with kidney diseases. Literature review

COVID-19 is a severe acute respiratory disease caused by the SARS-CoV-2 virus. Although COVID-19 is characterized mainly by diffuse alveolar damage and acute respiratory failure, in some cases COVID-19 may acquire extra-respiratory features, including renal dysfunction that has existed earlier or developed de novo. The reasons for the extra-respiratory manifestations are biological properties of SARS-CoV-2 based on its multiple organ tropism. It has been shown that at least 50% of patients hospitalized for COVID-19 have proteinuria, hematuria, and signs of renal dysfunction, which in some cases reaches the degree of acute kidney injury (AKI). Here we present a review that discusses the clinical aspects and possible pathophysiological mechanisms of kidney damage in COVID-19. It is believed that renal damage observed in this disease is the result of a complex mechanism induced directly or indirectly by SARS-CoV-2 with the development of acute kidney injury. Two main pathophysiological mechanisms of kidney damage in COVID-19 are discussed. The first of them is the direct cytopathic effect of SARS-CoV-2 on the renal epithelium with the development of acute tubulonecrosis. The second mechanism is the cytokine storm syndrome that results from hyperactivation of the immune system with the development of acute renal and multiorgan inflammatory damage accompanied by hypoxia, persistent hypotension, rhabdomyolysis, hyperactivation of the coagulation cascade, and microcirculation disorders. From a clinical point of view, it should be noted that signs of kidney damage are associated with an increase in the severity of COVID-19 and a poor outcome of the disease, and the prognosis becomes the worst with the development of AKI (the risk of death may increase by 5.3 times). The incidence of COVID-19 in patients with ESRD is higher than in the general population. The most typical for these patients is a severe course of the disease, which determines the increased mortality in comparison with the general population, caused by a respiratory failure with hyperactive inflammation, cytokine storm, hemodynamic, and multiple organ failures.

COVID-19, цитопатический эффект вируса SARS-CoV-2, цитокиновый шторм, острое повреждение почек, терминальная хроническая почечная недостаточность, COVID-19, the cytopathic effect of SARS-CoV-2, cytokine storm, acute kidney injury, end-stage renal disease

1. World Health Organization. Coronavirus disease (COVID-2019) situation reports. Available at: https:// www.who.int/emergencies/diseases/novelcoronavirus-2019/situation-reports. Accessed March 16, 2020;

2. Perico L. Benigni A., Remuzzi G. Should COVID-19 Concern Nephrologists. Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron 2020 DOI: 10.1159/000507305

3. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Arcgis Johns Hopkins University

4. Guan W.J., Ni Z.Y., Hu Y. et al. China Medical Treatment Expert Group for Covid-19: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708-1720. DOI: 10.1056/NEJMoa2002032.

5. Huang Ch., Wang Y., Li X., Ren L. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497-506. doi.org/10.1016/S0140-6736 (20)30183-5.

6. Li L., Huang T., Wang Y., Wang Z. et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis J Med Virol. 2020; 1-7. DOI: 10.1002/jmv.25757.

7. Zhou F., Yu T., Du R., Fan G. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62 doi.org/10.1016/ S0140-6736(20)30566-3.

8. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J Am Med Assoc. 2020. doi:10.1001/jama.2020.2648.

9. CDC COVID-19 Response Team: Severe outcomes among patients with Coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 343-346.

10. CDC: Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019- COVID-NET, 14 states, March 1-30, 2020, 2020. Available at: https://www.cdc.gov/ mmwr/volumes/69/wr/mm6915e3.htm. Accessed April 14, 2020

11. Li Z., Wu M., Yao J., Guo J., Liao X. et al. Caution on Kidney Dysfunctions of COVID-19 Patients. medRxiv preprint doi: https://doi.org/10.1101/2020.02.08.20021212.

12. Cheng Y., Luo R., Wang K., Zhang M. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney International 2020; 97, 829-838; https://doi.org/10.1016/j.kint.2020.03.005

13. Henry B.M., Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID 19) infection. International Urology and Nephrology. 2020; 52:1193-1194 https://doi.org/10.1007/s11255-020-02451-9.

14. Yang Q., Yang X. Incidence and risk factors of kidney impairment on patients with COVID-19: A meta-analysis of 10180 patients. PLOS One 2020; 15(11): e0241953 doi: 10.1371/journal.pone.0241953

15. SARS-CoV-2 Surveillance Group, Istituto Superiore di Sanità (2020) Characteristics of COVID-19 patients dying in Italy. https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-analysis-of-deaths.

16. Столяревич Е.С. Фролова Н.Ф., Артюхина Л.Ю., Варясин В.В. Поражение почек при Covid-19: клинические и морфологические проявления почечной патологии у 220 пациентов, умерших от Covid-19. Нефрология и Диализ. 2020, т 22 Спецвыпуск, стр 46-55. DOI: 10.28996/2618-9801

17. Pei G., Zhang Z., Peng J., Liu L. et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia JASN 2020; 31: 1157-1165, doi: 10.1681/ASN.2020030276.

18. Batlle D., Soler M.J., Sparks M.A.,Hiremath S. et al. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. J. Am. Soc. Nephrol. 2020, 31, 1380-1383. doi: org/10.1681/ASN.2020040419.

19. Gagliardi I., Patella G., Michael A., Serra R. еt al. COVID-19 and the Kidney: From Epidemiology to Clinical Practice J. Clin. Med. 2020, 9, 2506; doi:10.3390/jcm9082506.

20. Peleg Y., Kudose S., D’Agati V., Siddall E. et al. Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep 2020. 5: 940-945;doi.org/10.1016/j.ekir.2020.04.017.

21. Kissling S., Rotman S., Gerber C., Halfon M. et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney International. 2020; 98:228-239.

22. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 16:181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052.

23. Ye M., Wysocki J., William J., Cokic M.J., Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: Implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 2006;17:3067-3075.

24. Zou X., Chen K., Zou J., Han P.et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 2020; 14(2):185-192. doi:10.1007/s11684-020-0754-0

25. Ferrey A.J., Choi G., Hanna R.M., Chang Y., Tantisattamo E. et al. A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease Am J Nephrol 2020 DOI: 10.1159/000507417.

26. Qi F., Qian S., Zhang S., Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020; 21;526(1):135-140. doi: 10.1016/j.bbrc.2020.03.044.

27. Puelles V.G., Lütgehetmann M., Lindenmeyer M.T., Sperhake J.P. et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020; 383(6):590-592. doi: 10.1056/NEJMc2011400.

28. Braun F., Lütgehetmann M., Pfefferle S., Wong M.N. et al. SARS-CoV-2 renal tropism associates with acute kidney injury Lancet. 2020; Aug 29;396(10251):597-598. doi: 10.1016/S0140-6736(20)31759-1.

29. Ko G.J., Rabb H., Hassoun H.T. Kidney-Lung Crosstalk in the Critically Ill Patient. Blood Purif. 2009;28:75-83 DOI: 10.1159/000218087

30. Maeda A., Hayase N., Doi K. Acute Kidney Injury Induces Innate Immune Response and Neutrophil Activation in the Lung. Front. Med. 2020;7:7:565010. doi: 10.3389/fmed.2020.565010.

31. Werion A., Belkhir L., Perrot M., Schmit G. et al. SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney International 2020; 98, 1296-1307; https://doi.org/10.1016/ j.kint.2020.07.019

32. Diao B., Wang C., Wang R., Feng Z. et al. Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. medRxiv preprint doi: https://doi.org/10.1101/2020.03.04.20031120].

33. Su H., Yang M., Wan C., Yi L., Tang F. et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020 Jul;98(1):219-227. doi: 10.1016/j.kint.2020.04.003.

34. Calomeni E., Satoskar A., Ayoub I., Brodsky S. et al. Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19. Kidney International 2020; 98, 233-234; https://doi.org/10.1016/ j.kint.2020.05.003

35. Braun F., Huber T.B. and Puelles V. G. Proximal tubular dysfunction in patients with COVID-19: what have we learnt so far? Kidney International 2020. 98: 1092-1094; doi: 10.1016/j.kint.2020.09.002.

36. Zhang F., Liang Y. Potential risk of kidney vulnerable novel coronavirus 2019 infection Am J. Physiol Renal Physiol 2020 May 1; 318: F1136-F1137

37. Taverna Gianluigi, Di Francesco Simona, Borroni Elena Monica, Yiu Daniel et al. The kidney, COVID 19, and the chemokine network: an intriguing trio. International Urology and Nephrology https://doi.org/10.1007/s11255-020-02579-8

38. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18: 844-847.

39. Batlle D., Soler M.J., Sparks M.A. et al. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. J. Am. Soc. Nephrol. 2020; 31(7):1380-1383. doi: 10.1681/ASN.2020040419.

40. Wang K., Chen W., Zhou Y.-S. et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. BioRxiv. 2020. doi: https://doi.org/10.1101/2020.03.14.988345

41. Naicker S., Yang C.-W., Hwang S.-J., Liu Bi-C. et al. The Novel Coronavirus 2019 epidemic and kidneys. Kidney International 2020. 97: 824-828; doi: 10.1016/j.kint.2020.03.001

42. Hansrivijit P., Qian C., Boonpheng B., Thongprayoon C. et al. Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis J Investig Med. 2020;0:1-10. doi:10.1136/jim-2020-001407

43. Robbins-Juarez S.Y., Qian L., King K.L., Stevens J.S. et al. Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis Kidney Int Rep (2020) 5, 1149-1160; doi.org/10.1016/j.ekir.2020.06.013

44. Hirsch J.S., Ng J.H., Ross D.W., Sharma P. et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney International. 2020; 98: 209-218; doi.org/10.1016/j.kint.2020.05.006

45. Syed-Ahmed M.,Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease Adv Chronic Kidney Dis. 2019;26(1):8-15

46. Valeri A.M., Robbins-Juarez S. Y, Stevens J.S., Ahn W. et al. Presentation and Outcomes of Patients with ESKD and COVID-19. JASN. 2020; 31:1409-1415. doi: https://doi.org/10.1681/ASN.2020040470

47. Rombolà G., Hedemperger M., Pedrini L., Farina M. et al. Practical indications for the prevention and management of SARS CoV 2 in ambulatory dialysis patients: lessons from the frst phase of the epidemics in Lombardy. Journal of Nephrology https://doi.org/10.1007/s40620-020-00727-y.

48. Corbett R. W., Blakey S., Nitsch D., Loucaidou M. et al. Epidemiology of COVID-19 in an Urban Dialysis Center. JASN 31: 1815-1823, 2020. doi: https://doi.org/10.1681/ASN.2020040534.

49. Savino M., Casula A., Santhakumaran S., Pitcher D. et al. Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARS-CoV-2: A UK Renal Registry data analysis PLOS ONE 2020| https://doi.org/10.1371/journal.pone.0241263.

50. Ibernon M., Bueno I., Rodríguez-Farré N, Ruiz P. et al. The impact of COVID-19 in hemodialysis patients: Experience in a hospital dialysis unit. Hemodialysis International 2020 Nov 22;10.1111/hdi.12905. doi: 10.1111/hdi.12905

51. Li C., Yonglong M., M, Can T, Dongdong M. et al. (2020) An Analysis on the Clinical Features of MHD Patients with Coronavirus Disease 2019: A Single Center Study. https://doi.org/10.21203/rs.3.rs-18043/v1 https://www.researchsquare.com/article/rs-18043/v1

52. Jager K. J., Kramer A., Chesnaye N. C., Couchoud C. et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020 Dec; 98(6):1540-1548. doi:10.1016/j.kint.2020.09.006. Epub 2020 Oct 15

53. Manganaro M., Baldovino S. on behalf of The Working group of the Piedmont and Aosta Valley Section of the SIN. First considerations on the SARS CoV 2 epidemic in the Dialysis Units of Piedmont and Aosta Valley, Northern Italy. J. Nephrol. 2020; 33(3):393-395. doi: 10.1007/s40620-020-00732-1.

54. Quintaliani G., Reboldi G., Napoli A.Di, Nordio M. et al. Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID 19 pandemic: survey of the Italian Society of Nephrology. Journal of Nephrology 2020; 33:725-736 doi: 10.1007/s40620-020-00794-1

55. Arslan H., Musabak U., Soy E. H. A., Azap O. K. Incidence and Immunologic Analysis of Coronavirus Disease (COVID-19) in Hemodialysis Patients: A Single-Center Experience. Experimental and Clinical Transplantation 2020; 3: 275-283 DOI: 10.6002/ect.2020.0194.

56. Wang R., Liao C., He H., Hu C. et al. COVID-19 in Hemodialysis Patients: A Report of 5 Cases. Am J Kidney Dis. 2020; 76(1):141-143. doi: 10.1053/ j.ajkd.2020.03.009.

57. Xiong М F., Tang H., Liu L., Tu C. et al. Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China J Am Soc Nephrol. 2020; 31(7): 1387-1397. doi: 10.1681/ASN.2020030354

58. Goicoechea M., Ca´mara L. A. S., Macı´as N., de Morales A. et al. COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. Kidney International 2020; 98: 27-34. doi: 10.1016/j.kint.2020.04.031.

59. Scarpioni R., Manini A., Valsania T., De Amicis S. et al. COVID-19 and its impact on nephropathic patients: the experience at Ospedale “Guglielmo da Saliceto” in Piacenza. G Ital Nefrol. 2020; Apr 9; 37(2): 1-4.

60. Creput C., Fumeron C., Toledano D., Diaconita M., Izzedine H. COVID-19 in Patients Undergoing Hemodialysis: Prevalence and Asymptomatic Screening During a Period of High Community Prevalence in a Large Paris Center. Kidney Med. 2020; 2(6): 716-723.

61. Alberici F., Delbarba E., Manenti C., Econimo L. et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney International. 2020; 98: 27-34 doi: 10.1016/j.kint.2020.04.030.

62. Ma Y., Diao B., Lv X., Liang W et al. COVID-19 in hemodialysis (HD) patients: Report from one HD center in Wuhan, China. medRxiv preprint doi: https://doi.org/10.1101/2020.02.24.20027201

63. Ossareh S., Bagheri S. M., Abbasi M., Abolfathi S., Bohlooli A. Role of Screening for COVID-19 in Hemodialysis Wards, Results of a Single Center Study. IJKD 2020;14:389-98.

64. Clarke C., Prendecki M., Dhutia A., Ali M. A. et al. High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. JASN. 2020; 31: 1969-1975.

65. Albalate M., Arribas P., Torres E., Cintra M. et al. High Prevalence of Asymptomatic COVID-19 in Haemodialysis: Learning Day by Day in the First Month of the COVID-19 Pandemic. Nefrologia. 2020; 40 (3): 279-286 doi 1016/j.nefro.2020.04.005

66. Ng H., Hirsch J.S., Wanchoo R., Sachdeva M. et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020 Dec;98(6):1530-1539. doi: 10.1016/j.kint.2020.07.030.

67. Fisher M., Yunes M., Mokrzycki M.H., Golestaneh L. et al. Chronic Hemodialysis Patients Hospitalized with COVID-19: Short-term Outcomes in the Bronx, New York. Kidney360 August 020, 1 (8) 755-762; DOI: https://doi.org/10.34067/KID.0003672020.

68. Sánchez-Álvarez J. E., Pérez Fontán M., Martínc C. J.,. Pelícano M. B. Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). Nefrologia. 2020; 40(3):272-278.

69. Фролова Н.Ф., Ушакова А.И., Усатюк С.С., Артюхина Л.Ю. и соавт. COVID-19 у больных с терминальной стадией хронической болезни почек: анализ работы одного диализного центра. Инфекционные болезни: новости, мнения, обучение. 2021. т. 10, № 1. стр. 14-23. DOI: https://doi.org/10.33029/2305-3496-2021-10-1-14-23